- United States
- /
- Biotech
- /
- NasdaqCM:CDIO
Cardio Diagnostics Holdings Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Cardio Diagnostics Holdings (NASDAQ:CDIO) Full Year 2024 Results
Key Financial Results
- Net loss: US$8.38m (flat on FY 2023).
- US$0.31 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cardio Diagnostics Holdings EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 37%. Earnings per share (EPS) exceeded analyst estimates by 14%.
The company's shares are up 6.1% from a week ago.
Risk Analysis
Be aware that Cardio Diagnostics Holdings is showing 6 warning signs in our investment analysis and 4 of those shouldn't be ignored...
The New Payments ETF Is Live on NASDAQ:
Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.
Explore how this launch could reshape portfolios
Sponsored ContentNew: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:CDIO
Cardio Diagnostics Holdings
Develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Flawless balance sheet with moderate risk.
Market Insights
Weekly Picks
THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

The Quiet Giant That Became AI’s Power Grid
Recently Updated Narratives

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price
Deep Value Multi Bagger Opportunity

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)
Trending Discussion
